局部晚期非小细胞肺癌质子治疗与调强光子放疗联合同步化疗的长期结局:前瞻性随机试验事后分析
该前瞻性随机试验事后分析比较了被动散射质子治疗(PSPT)与调强光子放疗(IMRT)联合同步化疗治疗局部晚期非小细胞肺癌的长期毒性及疾病结局。
要点
- PSPT组放射性相关MACE较少(1例 vs 9例),可能与冠状动脉受量降低有关。
- 局部失败和无进展生存两组无差异,生存结局与RTOG 0617相当。
核心结论
- 当IMRT和PSPT计划均满足肺剂量体积约束时,两种放疗方式的肺毒性和局部失败无差异。
- PSPT组放射性相关MACE较少,推测源于冠状动脉受量降低。
- 生存结局与RTOG 0617试验相当。
研究设计与样本
- 前瞻性随机试验的事后分析,比较被动散射质子治疗(PSPT)与调强光子放疗(IMRT)联合同步化疗。
- 中位随访28.5个月(IMRT组29.7个月,PSPT组26.2个月),7例失访。
主要发现
- IMRT组2例、PSPT组0例发生5级放射性肺炎。
- 10例肯定/可能与放疗相关的MACE中,PSPT组1例,IMRT组9例。
- 食管毒性两组无差异,包括7例3级狭窄和1例第二原发癌。
- 局部失败和无进展生存两组无差异。
关键数值与推荐
- 既存肺疾病和平均肺剂量与≥3级放射性肺炎相关。
- 冠状动脉剂量可能与MACE相关。
- 肿瘤体积和放疗剂量影响生存结局。
临床怎么用
- 在肺剂量体积约束可满足时,IMRT与PSPT的肺毒性和局部控制相似。
- 对于心脏受量可能较高的患者,PSPT或可减少放射性相关MACE。
- 需关注既存肺疾病和平均肺剂量以降低≥3级放射性肺炎风险。
局限性
- 为随机试验的事后分析。
- 中位随访时间PSPT组短于IMRT组(26.2个月 vs 29.7个月)。
- 7例患者失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report long-term toxicity and disease outcomes from a randomized trial comparing passive scattering proton therapy (PSPT) and intensity modulated photon radiation therapy (IMRT), both with concurrent chemotherapy, for non-small cell lung cancer. METHODS AND MATERIALS: One hundred forty-nine patients with locally advanced non-small cell lung cancer were randomly assigned to IMRT or PSPT; 147 completed the assigned treatment. Local failure, radiation pneumonitis (RP), major adverse cardiac events (MACEs), long-term esophageal toxicity, and survival were estimated and compared between IMRT and PSPT. Risk factors for each endpoint were analyzed using Cox proportional hazards regression or competing-risks regression. RESULTS: The median follow-up time was 28.5 months (29.7 months IMRT, 26.2 months PSPT); 7 patients were lost to follow-up. Grade ≥3 RP was experienced by 10 patients in the IMRT group (10.9%) and 6 in the PSPT group (10.5%; P = .98); 2 patients treated with IMRT and no patients treated with PSPT had grade 5 RP. Pre-existing pulmonary disease and mean lung dose were found to be associated with grade ≥3 RP. Esophageal toxicity rates did not differ between groups and consisted of 7 grade 3 strictures and 1 secondary cancer. Of the 10 definitely/possibly radiation-related MACEs, 1 was in PSPT, and 9 were in IMRT; doses to coronary arteries may have been associated with MACE. No differences were found in local failure or progression-free survival. Tumor volume and radiation dose influenced survival outcomes. CONCLUSIONS: When both IMRT and PSPT plans met dose-volume constraints for the lung, no differences were found in lung toxicity or local failure after IMRT versus PSPT, consistent with our original findings. PSPT led to fewer cases of radiation-related MACE, presumably from reduced radiation dose to the coronary arteries. Survival outcomes were comparable to those of Radiation Therapy Oncology Group 0617, a phase 3 trial that included only patients with stage IIB to IIIA disease and good performance status.
引用
- Su T, Xu T, Chen M, et al. Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42173326. doi:10.1016/j.ijrobp.2026.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。